In locally advanced (stage III) NSCLC, most fit patients receive concurrent chemotherapy with a platinum-doublet and RT (CCRT), followed by one year of durvalumab (anti-PD-L1) therapy [3]
J.RogerV
The April 30, 2026 503B bulks-list exclusion proposal targets large outsourcing facilities, not patient-specific 503A telehealth
Demand is expected to be driven by specialist access constraints and consumer convenience
There is also some evidence that it may help increase sperm count (Balercia et al., 2004
Across the cagrilintide clinical program, the dominant tolerability issues have been gastrointestinal: nausea, reduced appetite, constipation, and, less commonly, vomiting a profile shared with pramlintide and with GLP-1 agonists, and mechanistically expected from a compound that slows the stomach and engages the area postrema